Biomea Fusion, Inc.
BMEANext catalyst
icovamenib
Type 2 Diabetes
Get an email about BMEA's next catalysts
Track Biomea Fusion (BMEA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 1 past
icovamenib Phase 2 Est. Readout
Estimated primary completion for icovamenib trial (NCT07502495) in Type 2 Diabetes. Topline data typically follows completion by weeks to months.
Sourceicovamenib Phase 2 Est. Readout
Estimated primary completion for icovamenib trial (NCT07502508) in Type 2 Diabetes. Topline data typically follows completion by weeks to months.
SourceHow BMEA's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BMF-219 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
icovamenib | Phase 2 | Type 2 Diabetes | - | - |
Frequently asked questions
What is in Biomea Fusion, Inc.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in Biomea Fusion, Inc.'s (BMEA) pipeline across Phase 2. Its lead program is icovamenib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Biomea Fusion, Inc.'s next FDA catalyst?β
Biomea Fusion, Inc.'s (BMEA) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BMEA biotech catalysts?β
Add BMEA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biomea Fusion, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
